FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely addictology, and deals with relief of alcohol abstinence syndrome by blockade of benzodiazepine receptors. For this purpose anexate is introduced intravenously. Introduction is performed twice in strict succession through fixed 3 hours in dose 0.5 mg, reaching complete reduction of main clinical manifestations of alcohol abstinence syndrome. Duration of each introduction is 3-5 minutes.
EFFECT: method ensures increase of treatment efficiency and reduction of terms of relieving psychoneurologic and somato-vegetative manifestations of alcohol abstinence.
1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ALLEVIATING COMPLICATED ABSTINENCE SYNDROME | 1992 |
|
RU2067442C1 |
| METHOD FOR INTERRUPTING ALCOHOLIC ABSTINENT SYNDROME, DELIRIUM TREMENS, ACUTE ALCOHOLIC HALLUCINOSIS | 2001 |
|
RU2215527C2 |
| METHOD OF REHABILITATION OF PATIENTS WITH ALCOHOLISM | 2009 |
|
RU2436573C2 |
| METHOD FOR OPTIMIZING THERAPY OF ALCOHOLIC ABSTINENCE SYNDROME | 2004 |
|
RU2262963C1 |
| METHOD OF ABSTINENCE SYNDROME TREATMENT | 2010 |
|
RU2422139C1 |
| METHOD FOR THE TREATMENT OF WITHDRAWAL PSYCHOSIS IN PERSONS WITH DEPENDENCE ON SEDATIVES AND HYPNOTICS BELONGING TO THE GROUP OF SYNTHETIC AGONISTS OF GAMMA-AMINOBUTYRIC ACID RECEPTORS, BUTYROLACTONE AND 1,4-BUTANEDIOL | 2022 |
|
RU2788894C1 |
| METHOD OF STOPPING ALCOHOL ABSTINENCE | 2010 |
|
RU2428984C1 |
| METHOD OF TREATING ABSTINENCE SYNDROME, IN ORDER TO PREVENT DEVELOPING PSYCHOSIS, IN INDIVIDUALS WITH DEPENDENCE ON SYNTHETIC AGONISTS OF GAMMA-AMINOBUTYRIC ACID RECEPTORS: BUTYROLACTONE, 1,4-BUTANEDIOL | 2020 |
|
RU2739192C1 |
| METHOD OF ALCOHOLIC ABSTINENCE SYNDROME REDUCTION | 2006 |
|
RU2327474C1 |
| ANTI-ALCOHOL TEA FROM MEDICATIVE HERBS | 2003 |
|
RU2254137C1 |
